Seaport Completes Spin-Off from PureTech and Raises $100 Million in Series A Financing 

Seaport Completes Spin-Off from PureTech and Raises $100 Million in Series A Financing 

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale represented Seaport Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing novel neuropsychiatric medicines, in connection with its spin-off from PureTech Health and its $100 million oversubscribed Series A financing round. The transactions enable Seaport to progress its pipeline of novel neuropsychiatric medicines based on its Glyph™ Technology Platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce hepatotoxicity and other side effects to advance active drugs that were previously held back by those limitations. The financing was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and PureTech. The WilmerHale team representing Seaport consisted of Stuart Falber, Sarah Hogan, Will Myer, Pooja Sudarshan, Adam Camiel, Ben Goldfein, Matthew O’Malley, Scott Kilgore, Julie Hogan Rodgers and Kim Wethly.  

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel